People: Horizon Pharma Inc (HZNP.W)
HZNP.W on CBOE When Trading NASDAQ Global Select Market
2.37USD
23 May 2013
2.37USD
23 May 2013
Price Change (% chg)
$-0.05 (-2.07%)
$-0.05 (-2.07%)
Prev Close
$2.42
$2.42
Open
$2.33
$2.33
Day's High
$2.37
$2.37
Day's Low
$2.33
$2.33
Volume
700
700
Avg. Vol
1,658
1,658
52-wk High
$8.44
$8.44
52-wk Low
$1.98
$1.98
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Timothy Walbert |
45 | 2010 | Chairman of the Board, President, Chief Executive Officer |
Robert De Vaere |
55 | 2010 | Chief Financial Officer, Executive Vice President |
Jeffrey Sherman |
58 | 2011 | Chief Medical Officer, Executive Vice President - Development, Regulatory Affairs, Manufacturing |
Todd Smith |
43 | 2012 | Executive Vice President, Chief Commercial Officer |
Michael Grey |
2012 | Lead Independent Director | |
Jeffrey Bird |
52 | 2010 | Independent Director |
Jean-Francois Formela |
56 | 2010 | Independent Director |
Jeff Himawan |
47 | 2010 | Independent Director |
Ronald Pauli |
52 | 2011 | Independent Director |
Gino Santini |
56 | 2012 | Independent Director |
Biographies
| Name | Description |
|---|---|
Timothy Walbert |
Mr. Timothy P. Walbert is Chairman of the Board, President, Chief Executive Officer of Horizon Pharma Inc. Mr. Walbert has served as chairman of board of directors and president and chief executive officer since inception in March 2010. Mr. Walbert has also served as the president and chief executive officer of Horizon Pharma USA since June 2008 and on its board of directors since July 2008. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., or IDM, a biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. From January 2006 to May 2007, Mr. Walbert served as executive vice president, commercial operations of NeoPharm, Inc., a biopharmaceutical company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager, Immunology, where he led the global development and launch of HUMIRA, which exceeded $9.0 billion in 2012 sales, and divisional vice president, global cardiovascular strategy at Abbott, a broad-based healthcare company, now AbbVie. From April 1998 to June 2001, Mr. Walbert served as director, Celebrex North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company, or G.D. Searle, a pharmaceutical company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College, in Allentown, Pennsylvania. Mr. Walbert also serves on the board of directors of XOMA Ltd. (NASDAQ: XOMA), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT, a World Business Chicago (WBC) led council of technology leaders and the Greater Chicago Arthritis Foundation. |
Robert De Vaere |
Mr. Robert J. De Vaere is Chief Financial Officer, Executive Vice President of Horizon Pharma Inc. Mr. De Vaere has served as executive vice president and chief financial officer since inception in March 2010 and as the executive vice president and chief financial officer of Horizon Pharma USA since October 2008. From May 2007 to June 2009, Mr. De Vaere served as senior vice president, finance and administration and chief financial officer at IDM, which was acquired by Takeda in 2009. From August 2006 to April 2007, Mr. De Vaere served as chief financial officer at Nexa Orthopedics, Inc., a medical device company, which was acquired by Tornier, Inc. in February 2007. From August 2005 to March 2006, Mr. De Vaere served as vice president, finance and administration and chief financial officer at IDM. From May 2000 to August 2005, Mr. De Vaere served as vice president and chief financial officer at Epimmune Incorporated, a pharmaceutical company focused on the development of vaccines, which was combined with IDM in August 2005. Prior to 2000, Mr. De Vaere served as vice president of finance and administration and chief financial officer at Vista Medical Technologies, Inc., a medical device company. Mr. De Vaere received his B.S. from the University of California, Los Angeles. |
Jeffrey Sherman |
Dr. Jeffrey W. Sherman, M.D., FACP., is Chief Medical Officer, Executive Vice President - Development, Regulatory Affairs, Manufacturing of Horizon Pharma Inc. Dr. Sherman has served as executive vice president, development, regulatory affairs, manufacturing and chief medical officer since June 2011, as executive vice president, development and regulatory affairs and chief medical officer since inception in March 2010 and as the executive vice president, development and regulatory affairs and chief medical officer of Horizon Pharma USA since June 2009. From June 2009 to June 2010, Dr. Sherman served as president and board member of the Drug Information Association, or DIA, a nonprofit professional association of members who work in government regulatory, academia, patient advocacy, and the pharmaceutical and medical device industry. Dr. Sherman is now a past president of DIA and serves as DIA liaison to the Clinical Trial Transformation Initiative, a public-private partnership founded by the FDA and Duke University to improve the quality and efficiency of clinical trials. Dr. Sherman is an adjunct assistant professor of Medicine at the Northwestern University Feinberg School of Medicine and is a member of a number of professional societies as well as a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. Dr. Sherman received his M.D. from the Rosalind Franklin University/Chicago Medical School. Dr. Sherman completed an internal medicine internship, residency and chief medical residency at Northwestern University as well as fellowship training at the University of California, San Francisco, or UCSF. Dr. Sherman was also a research associate at the Howard Hughes Medical Institute at UCSF. |
Todd Smith |
Mr. Todd N. Smith is Executive Vice President, Chief Commercial Officer of Horizon Pharma Inc. Mr. Smith has served as executive vice president and chief commercial officer since February 2012. Prior to that, Mr. Smith served as senior vice president, sales, marketing and business development of Horizon Pharma USA since October 1, 2010. From January 2009 to August 2010, Mr. Smith served as vice president, global marketing, strategy and business development at Fenwal, Inc., a global medical device technology company, and managed a team of approximately 100 people located in the U.S. and abroad. Mr. Smith also served as vice president of automated business from May 2008 to January 2009, and amicus category business unit director from November 2007 to May 2008 at Fenwal. From April 2006 to November 2007, Mr. Smith served as director of marketing, virology franchise, at Abbott, now AbbVie, and managed marketing and field teams of approximately 85 people. From March 2004 to April 2006, Mr. Smith served as director of sales, virology franchise, at Abbott Laboratories managing a sales and training team of approximately 200 people. From April 2003 to April 2004, Mr. Smith served as deputy director – product management, segment markets and managed care, at Bayer Biological Products, a pharmaceutical company. At Bayer Biological Products, Mr. Smith also served as associate director of coagulation products from April 2002 to April 2003. From April 2001 to April 2002, Mr. Smith served as associate director of business development at Achillion Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease. Prior to April 2001, Mr. Smith served as a regional sales manager, product manager and sales specialist at Agouron Pharmaceuticals, Inc., a pharmaceutical company, which was acquired by Pfizer Inc. in February 2000. Mr. Smith received his B.A. from Norwich University. |
Michael Grey |
Mr. Michael G. Grey is Lead Independent Director of Horizon Pharma, Inc. Mr. Grey has served on board of directors since September 2011 and as lead independent director of the Company since August 2012. Mr. Grey currently serves as president and chief executive officer at Lumena Pharmaceuticals, Inc. and is a venture partner at Pappas Ventures. Mr. Grey holds over 30 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to Lion Bioscience in 2001) and president of BioChem Therapeutic Inc. For approximately 20 years, Mr. Grey served in various roles with Glaxo, Inc. and Glaxo Holdings, P.L.C., culminating in his position as vice president, corporate development and director of international licensing. Mr. Grey also serves on the board of directors of BioMarin Pharmaceutical Inc. and Selventa, Inc. Mr. Grey received a B.S. in chemistry from the University of Nottingham in the United Kingdom. |
Jeffrey Bird |
Dr. Jeffrey W. Bird, M.D., Ph.D., is Independent Director of Horizon Pharma Inc. Dr. Bird has served on board of directors since inception in March 2010 and has served on the board of directors of Horizon Pharma USA since July 2007. Dr. Bird has been a managing director of the general partner of Sutter Hill Ventures, a California Limited Partnership, a venture capital firm, since July 2003, and CEO of Verinata Health since May 2012. Dr. Bird also serves on the boards of directors of Artemis Health, Inc., Drais Pharmaceuticals, Inc., NuGen Technologies, Inc., Portola Pharmaceuticals, Inc., Restoration Robotics, Inc., Threshold Pharmaceuticals, Inc. and ViroBay, Inc. From 1988 to 1990 and from 1992 to 2000, Dr. Bird served as a Senior Vice President, Business Operations at Gilead Sciences, Inc., a biopharmaceutical company, where he oversaw business development and commercial activities. Dr. Bird received his B.S. in biological sciences from Stanford University and his doctorate in cancer biology and M.D. from Stanford Medical School. |
Jean-Francois Formela |
Dr. Jean-Francois Formela, M.D., is Independent Director of Horizon Pharma Inc. Dr. Formela has served on board of directors since April 2010. Dr. Formela is a partner at Atlas Venture, a venture capital firm, which he joined in 1993. He also serves on the boards of directors of Annovation Biopharma, Inc., ARCA Biopharma, Inc., Arteaus Therapeutics, LLC and F-Star GmbH, and is the chairman of Egalet Ltd. as well as RaNA Therapeutics Inc., which he co-founded. Dr. Formela has been involved in the formation of companies such as Adnexus Therapeutics, Inc., which was acquired by Bristol-Myers Squibb Company, Archemix Corp., ArQule, Inc., Cellzome AG, which was acquired by GlaxoSmithKline plc, deCODE genetics, Inc., which was acquired by Amgen Inc, Exelixis, Inc., MorphoSys AG, NxStage Medical, Inc., and SGX, which was acquired by Lilly in 2008. He was also a board member of Biochem Pharma Inc., which was acquired by Shire Pharmaceuticals Group, and Novexel SA, which was acquired by Astrazeneca PLC in 2010. Prior to joining Atlas Venture, Dr. Formela served as a senior director of medical marketing and scientific affairs at Schering-Plough Corporation, a pharmaceutical company which merged with Merck & Co., Inc., where he was responsible for the marketing of Intron®A and directed U.S. Phase 4 clinical trials. Dr. Formela has also practiced emergency medicine at Necker University Hospital in Paris, France. Dr. Formela received his M.B.A. from Columbia University and his M.D. from Paris University School of Medicine. |
Jeff Himawan |
Dr. Jeff Himawan, Ph.D., is Independent Director of Horizon Pharma Inc. Dr. Himawan has served on board of directors since inception in March 2010 and has served on the board of directors of Horizon Pharma USA since July 2007. In 1999, Dr. Himawan joined Essex Woodlands Health Ventures, L.P., a venture capital firm, where he now serves as a managing director. Dr. Himawan also serves on the boards of directors of Catalyst Biosciences, Inc., MediciNova, Inc., Light Sciences Oncology, Inc., and Symphogen, Inc. Dr. Himawan also served on the board of directors of Iomai Corporation from 2001 to 2007, when it was acquired by Intercell AG. Dr. Himawan co-founded Seed-One Ventures, a venture capital firm, where from 1996 to 2001 he served as a managing director. From 1983 to 1996, Dr. Himawan was a scientist in academic and industrial settings. Dr. Himawan has written several patents in the fields of wireless communication, biotechnology and protein chemistry. Dr. Himawan received his B.S. in biology from the Massachusetts Institute of Technology and his doctorate in biological chemistry and molecular pharmacology from Harvard University. |
Ronald Pauli |
Mr. Ronald E. Pauli is Independent Director of Horizon Pharma, Inc. Mr. Pauli has served on board of directors since September 2011. Mr. Pauli is currently a financial consultant for the pharmaceutical and life science industries. Prior to that, Mr. Pauli held senior positions at a number of biopharmaceutical companies, including chief financial officer at Sagent Pharmaceuticals, Inc. and NeoPharm, Inc. and corporate controller and interim chief financial officer at Abraxis BioScience, Inc. (formerly American Pharmaceutical Partners, Inc.). In addition, Mr. Pauli previously served as corporate controller for Applied Power, Inc. and R.P. Scherer Corporation, held multiple finance positions at Kmart Corporation and began his career at Ernst & Whinney. Mr. Pauli received a B.S. in accounting from Michigan State University and a master’s degree in finance from Walsh College. |
Gino Santini |
Mr. Gino Santini is Independent Director of Horizon Pharma, Inc. Mr. Santini currently serves on the board of directors of AMAG Pharmaceuticals, Inc. and Allena Pharmaceuticals, Inc. and is retired from a distinguished career with Eli Lilly and Company that spanned nearly three decades. During his tenure at Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, president of the women’s health franchise and president of U.S. operations. Mr. Santini capped his career at Lilly as a member of the company’s executive committee and as the senior vice president of corporate strategy and business development. Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a master’s in business administration from the University of Rochester. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Timothy Walbert |
1,436,220 |
Robert De Vaere |
947,156 |
Jeffrey Sherman |
989,870 |
Todd Smith |
754,407 |
Michael Grey |
-- |
Jeffrey Bird |
-- |
Jean-Francois Formela |
-- |
Jeff Himawan |
-- |
Ronald Pauli |
-- |
Gino Santini |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Timothy Walbert |
0 | 0 |
Robert De Vaere |
0 | 0 |
Jeffrey Sherman |
0 | 0 |
Todd Smith |
0 | 0 |
Michael Grey |
0 | 0 |
Jeffrey Bird |
0 | 0 |
Jean-Francois Formela |
0 | 0 |
Jeff Himawan |
0 | 0 |
Ronald Pauli |
0 | 0 |
Gino Santini |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
DE VAERE ROBERT J |
20,544 | $2.36 |
ADATTO MICHAEL |
6,998 | $2.36 |
WALBERT TIMOTHY P |
20,749 | $2.36 |
SHERMAN JEFFREY W |
16,304 | $2.36 |
SMITH TODD N |
6,998 | $2.36 |
SMITH TODD N |
22,500 | $0.00 |
ADATTO MICHAEL |
22,500 | $0.00 |
WALBERT TIMOTHY P |
10,301 | $2.28 |
SHERMAN JEFFREY W |
8,208 | $0.00 |
SMITH TODD N |
3,349 | $0.00 |
ADATTO MICHAEL |
3,349 | $0.00 |
WALBERT TIMOTHY P |
33,211 | $0.00 |
DE VAERE ROBERT J |
8,208 | $0.00 |
QUAKER BIOVENTURES II L P |
546,198 | $0.01 |
BIRD JEFFREY W |
546,200 | $3.49 |
BIRD JEFFREY W |
29,156 | $3.49 |
QUAKER BIOVENTURES II L P |
208,334 | $0.00 |
SHERMAN JEFFREY W |
33,000 | $0.00 |
DE VAERE ROBERT J |
33,000 | $0.00 |
WALBERT TIMOTHY P |
42,000 | $0.00 |
BIRD JEFFREY W |
59,622 | $0.00 |
BIRD JEFFREY W |
11,721 | $0.00 |
ESSEX WOODLANDS HEALTH VENTURES FUND VII L P |
2,761,477 | $3.59 |
BIRD JEFFREY W |
7,000 | $3.59 |
SHERMAN JEFFREY W |
22,000 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
